drugset / Trial / NCT05492409
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
NaSingle-groupOpen-labelTreatment
Summary
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura
Timeline
- Start
- 2022-03-28
- Primary completion
- 2024-04-03
- Completion
- 2024-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GNR-069 | Protein / enzyme biologic | — | Subcutaneous |